2014
DOI: 10.12703/p6-102
|View full text |Cite
|
Sign up to set email alerts
|

Novel therapies for open-angle glaucoma

Abstract: Open-angle glaucoma is a multifactorial optic neuropathy characterized by progressive loss of retinal ganglion cells and their axons. It is an irreversible disease with no established cure. The only currently approved treatment is aimed at lowering intraocular pressure, the most significant risk factor known to date. However, it is now clear that there are other risk factors involved in glaucoma's pathophysiology. To achieve future improvements in glaucoma management, new approaches to therapies and novel targ… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
11
0

Year Published

2015
2015
2018
2018

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 18 publications
(11 citation statements)
references
References 77 publications
0
11
0
Order By: Relevance
“…Saving retinal ganglion cells and repairing damaged neurons could therefore be achieved not only by decreasing IOP but also by avoiding ischaemia, oxidative stress, excitotoxicity, defective axonal transport, trophic factor withdrawal, and neuroinflammation [3] . NMDA receptor antagonists, such as memantine, were tested in 1.3% of the clinical trials.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Saving retinal ganglion cells and repairing damaged neurons could therefore be achieved not only by decreasing IOP but also by avoiding ischaemia, oxidative stress, excitotoxicity, defective axonal transport, trophic factor withdrawal, and neuroinflammation [3] . NMDA receptor antagonists, such as memantine, were tested in 1.3% of the clinical trials.…”
Section: Discussionmentioning
confidence: 99%
“…Glaucoma medical treatment has evolved in the last few decades from IOP modulators (such as pilocarpine and timolol) to myriad new drugs that seek to exploit new treatment paradigms [3] . Some of the limitations related to the existing IOP-lowering therapies include harmful side effects, a significant proportion of non-responders, and the need for combination therapy to achieve target IOP [4] .…”
Section: Introductionmentioning
confidence: 99%
“…The disorders can be roughly divided into ''open-angle'' and ''closed-angle'' glaucoma, with open-angle glaucoma being the most common. Current drug therapies for treating glaucoma include eye drops containing prostaglandin, carbonic anhydrase inhibitors or beta-blockers, as well as surgical interventions [14]. Because patients are on chronic eye drop treatments for this disease, there is a significant unmet need for alternative delivery technologies that can reduce dosing frequency and improve patient compliance.…”
Section: Common Eye Diseases and Current Available Treatmentsmentioning
confidence: 99%
“…It therefore seems that new therapies and potential novel therapeutic targets must be developed to achieve progress in the treatment of this insidious disease. Prospecting of new targets for IOP lowering, molecules modulating ocular haemodynamics and treatments providing neuroprotection for RGCs are future promising strategies 9 . Furthermore, because RGC and the optic nerve are parts of the central nervous system (CNS), glaucomatous neuropathy is considered to share similar features with other neurodegenerative diseases (i.e., Alzheimer’s disease) 10 – 14 (Fig.…”
Section: Introductionmentioning
confidence: 99%